An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
Journal
Thyroid
Journal Volume
30
Journal Issue
9
Pages
1254-1262
Date Issued
2020
Author(s)
Bible K.C.
Menefee M.E.
Millward M.J.
Maples W.J.
Goh B.C.
Karlin N.J.
Kane M.A.
Adkins D.R.
Molina J.R.
Donehower R.C.
Lim W.-T.
Flynn P.J.
Richardson R.L.
Traynor A.M.
Rubin J.
Lorusso P.M.
Smallridge R.C.
Burton J.K.
Suman V.J.
Kumar A.
Voss J.S.
Rumilla K.M.
Kipp B.R.
Chintakuntlawar A.V.
Harris P.
Erlichman C.
Abstract
This trial prospectively confirmed pazopanib to have clinical activity and manageable toxicities in patients with progressive RAIR-DTC. Response to pazopanib, however, was not robustly forecast by early associated changes in Tg or MCV, by prior therapy, or by tumor mutational status. ClinicalTrials.gov NCT00625846.
SDGs
Publisher
Mary Ann Liebert Inc.
Type
journal article